Long-term global follow-up of adults with ATTR-CM treated with vutrisiran or other approved therapies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a global, observational, multicenter registry that enrolls adults diagnosed with transthyretin-mediated amyloid cardiomyopathy who are initiating vutrisiran or another approved ATTR-CM therapy. Sites will collect clinical characteristics, treatment patterns, health-related quality of life, and healthcare resource use during routine care. Participants will be followed for up to five years or until withdrawal, loss to follow-up, death, or study end. The dataset will be used to compare long-term effectiveness of vutrisiran versus other approved therapies in a real-world setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Has a diagnosis of ATTR-CM
* Is initiating treatment with vutrisiran or another approved ATTR-CM therapy

Exclusion Criteria:

* Is enrolled in an interventional clinical trial

Where it's running

• Clinical Trial Site
  Tucson, Arizona, United States Recruiting
• Clinical Trial Site
  Beverly Hills, California, United States Recruiting
• Clinical Trial Site
  La Jolla, California, United States Recruiting
• Clinical Trial Site
  Naples, Florida, United States Recruiting
• Clinical Trial Site
  Honolulu, Hawaii, United States Recruiting
• Clinical Trial Site
  Kansas City, Kansas, United States Recruiting

Study contacts

• Study coordinator: Clinical Trial Information Line
• Email: clinicaltrials@alnylam.com
• Phone: 1-877-ALNYLAM

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term safety of eplontersen in adults with transthyretin amyloidosis, including those with prior liver transplant or severe liver impairment

  This study will see if eplontersen remains safe over time for adults with transthyretin amyloidosis, including people who have had a liver transplant or have severe liver problems.

  Recruiting at 6 sites AstraZeneca · Los Angeles, California and 5 other locations · NCT07654855

• Nucresiran for transthyretin amyloidosis with cardiomyopathy

  This trial will test whether nucresiran can lower deaths and major heart-related events in people with transthyretin amyloidosis that affects the heart.

  Recruiting at 265 sites Phase 3 Alnylam Pharmaceuticals · La Jolla, California and 265 other locations · NCT07052903

• Acoramidis for ATTR-CM: Cardiac Imaging Study

  This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.

  Recruiting Phase 4 Eidos Therapeutics, a BridgeBio company · St Louis, Missouri · NCT07695701

• Evaluating NTLA-2001 for treating heart issues in patients with ATTR amyloidosis

  This study is testing if a new treatment called NTLA-2001 can improve heart function and health for people with heart issues caused by ATTR amyloidosis.

  Recruiting at 128 sites Phase 3 Intellia Therapeutics · Tucson, Arizona and 137 other locations · NCT06128629

• Annular ligament biopsy during endoscopic carpal tunnel surgery to screen for transthyretin amyloidosis

  This study tests whether a biopsy of the annular ligament during carpal tunnel surgery can reliably indicate transthyretin amyloidosis and match the results of the standard synovial biopsy.

  Recruiting Clinique Saint Jean, France · Montpellier · NCT07644325

• Eplontersen exposure during pregnancy and breastfeeding: outcomes

  This project collects reports to see if exposure to eplontersen during pregnancy or breastfeeding affects mothers, fetuses, or infants with transthyretin amyloidosis.

  Recruiting AstraZeneca · Frankfurt · NCT07205666

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.